



**華美化學與化工學會**  
**Chinese-American Chemical Society**  
**(CACCS)**

**Chinese-American Chemical Society Event**  
**at**  
**242<sup>nd</sup> American Chemical Society National Meeting**  
**(Fall 2011 ACS Annual Meeting)**

**Wednesday, August 31, 2011**

**Social Hours**  
5:30 - 6:30 PM

Open to all ACS meeting Attendees (Same location as banquet. Free of charge)

**Banquet and Keynote**  
6:30 - 9:00 PM

Empress Seafood Restaurant  
2825 West Alameda Ave, Denver, CO 80219-2901  
Phone: 303-922-2822

Tickets Available at ACS Registration, \$28/Person

## **Keynote Speech**

### **Building a Successful Drug Discovery Research Program in Academia**

**Shaomeng Wang, Ph.D.**

**Warner-Lambert/Parke-Davis Professor in Medicine**  
**Professor of Medicine, Pharmacology and Medicinal Chemistry**  
**Co-Director, Molecular Therapeutics Program**  
**University of Michigan Comprehensive Cancer Center**  
**University of Michigan**

## Keynote Speech

### Building a Successful Drug Discovery Research Program in Academia

Shaomeng Wang, Ph.D.

Warner-Lambert/Parke-Davis Professor in Medicine  
Professor of Medicine, Pharmacology and Medicinal Chemistry  
Co-Director, Molecular Therapeutics Program  
University of Michigan Comprehensive Cancer Center  
University of Michigan

#### Abstract

Drug discovery research in academia faces many challenges. Drug discovery research is multi-disciplinary in nature and requires close collaborations among computational chemists, medicinal chemists, biochemists, biologists, pharmacologists and structural biologists. It takes many years of research to obtain an ideal clinical candidate compound. Advancing a compound from laboratory into clinical development requires more resources than a typical R01 grant can provide. I will share with you my own personal experience on how to build a successful drug discovery research program in academia and to advance compounds into clinical development.

#### Biography

Dr. Shaomeng Wang received his B.S. in Chemistry from Peking University in 1986 and his Ph.D. in Chemistry from Case Western Reserve University in 1992. He did his postdoctoral training in drug design at the National Cancer Institute, NIH between 1992-1996. Dr. Wang started his academic career at Georgetown University as an Assistant Professor in 1996 and was promoted to Associate Professor in 2000. He joined the faculty at the University of Michigan Medical School as a tenured Associate Professor in 2001 and was promoted to Professor in 2006. He was named the Warner-Lambert/Parke-Davis Professor in Medicine in 2007. Dr. Wang serves as the Co-Director of the Molecular Therapeutics Program at the University of Michigan Comprehensive Cancer Center. Dr. Wang has been serving as a senior editor of the *Journal of Medicinal Chemistry* since 2009. Dr. Wang has published >200 peer-reviewed papers and >100 meeting abstracts, and is an inventor on > 20 international and US patents and patent applications.

Dr. Wang's primary research interest is the discovery and development of novel small-molecule therapeutics for the treatment of human cancer and other diseases and conditions. He has built a comprehensive drug discovery program at the University of Michigan. His research program consists of three research laboratories: a computational/informatics laboratory with expertise in lead identification and lead optimization using structure-based methods and informatics, a Chemistry laboratory with the capability of synthesizing complex small molecule ligands, and a biology/biochemistry/pharmacology laboratory with the capability and expertise for assay development, in-depth molecular mechanism studies in vitro and in vivo and evaluations of the biological activity of our designed compounds in relevant biochemical assays, cellular models and animal models of human cancer, as well as in vivo pharmacokinetics and pharmacodynamic analysis of our designed compounds in animal models. Dr. Wang has advanced two novel anticancer drugs into Phase I and Phase II human clinical trials and additional compounds in IND-enabling and advanced preclinical development.